Company Overview of Enzo Life Sciences, Inc.
Enzo Life Sciences, Inc. researches, develops, manufactures, licenses, and markets life science research reagents. It offers proteins, antibodies, peptides, small molecules, labeling probes dyes, ELISA kits, natural products, neurochemicals, enzymes, and inhibitors to provide life science researchers tools for target identification/validation, high content and gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. The company also provides DNA, RNA, and protein quantification assays; genomics and general molecular biology tools; molecular labels and probes; compound libraries; and enzymatic, protein, and immunological assays. In addition,...
10 Executive Boulevard
Farmingdale, NY 11735
Founded in 1976
Key Executives for Enzo Life Sciences, Inc.
President of Enzo Biochem Inc
Compensation as of Fiscal Year 2015.
Enzo Life Sciences, Inc. Key Developments
Enzo Life Sciences Announces Unaudited Earnings Results for the Third Quarter Ended April 30, 2015
Jun 9 15
Enzo Life Sciences announced unaudited earnings results for the third quarter ended April 30, 2015. For the quarter, the company reported softer demand combined with the effects of foreign currency resulted in a 9% decline in revenues, to $7.9 million, yet increased 2% from the previous fiscal quarter. During the quarter, foreign currency effect contributed to $0.4 million decline of product revenue. Royalty income declined to $0.4 million or 42% from the prior year period. Operating income totaled $1.0 million, compared to $6.1 million in the prior year period.
Enzo Life Sciences, Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2014
Dec 9 14
Enzo Life Sciences, Inc. reported unaudited earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported that product revenues continued to grow as a result of the increased focus on fewer but higher margin products, increasing 4%, to $8.0 million. Operating income totaled $1.6 million, compared to operating income of $1.4 million in the prior year. EBITDA declined to $1.7 million, compared to $2.3 million, a year ago primarily due to lower royalties.
Enzo Biochem Announces Settlement Agreement with PerkinElmer
Jun 23 14
Enzo Biochem, Inc. along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with PerkinElmer, Inc. and PerkinElmer Health Sciences, Inc. with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer, Inc. has agreed to pay $7,000,000 in escrow in settlement pursuant to the Agreement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|